{
    "clinical_study": {
        "@rank": "3017", 
        "arm_group": [
            {
                "arm_group_label": "Renal impairment grade 0", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Renal impairment grade 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Renal impairment grade 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Renal impairment grade 3", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the impact of impaired renal function on the pharmacokinetics of ART-123 in\n      patients with Disseminated Intravascular Coagulation.\n\n      To investigate the safety of ART-123 in patients with Disseminated Intravascular\n      Coagulation."
        }, 
        "brief_title": "Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Disseminated Intravascular Coagulation", 
        "condition_browse": {
            "mesh_term": [
                "Disseminated Intravascular Coagulation", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese Association for Acute Medicine-defined DIC criteria score >= 4\n\n          -  Written informed consent from patient or guardian\n\n        Exclusion Criteria:\n\n          -  Patients showing intracranial, pulmonary, gastrointestinal hemorrhage\n\n          -  Patients with a history of cerebrovascular disorders within the past 52 week\n\n          -  Patients with a history of hypersensitivity to the ingredients of ART-123\n             preparations\n\n          -  Pregnant women, nursing mothers or possibly pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704001", 
            "org_study_id": "ART-123 IV-2"
        }, 
        "intervention": {
            "arm_group_label": [
                "Renal impairment grade 0", 
                "Renal impairment grade 1", 
                "Renal impairment grade 2", 
                "Renal impairment grade 3"
            ], 
            "description": "380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days", 
            "intervention_name": "ART-123", 
            "intervention_type": "Drug", 
            "other_name": "Recomodulin\u2122"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ART-123", 
            "Disseminated Intravascular Coagulation", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "October 16, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oita", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment", 
        "overall_contact": {
            "email": "ct-info@om.asahi-kasei.co.jp", 
            "last_name": "Asahi Kasei Pharma Corporation", 
            "phone": "81-(0)3-3296-5337"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Cmax, Area Under Curve, T1/2,CLtot,CLR", 
                "measure": "Composite of Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0,2,4,8,24 hours post-dose"
            }, 
            {
                "measure": "Incidence rate of hemorrhage related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "from the start of infusion to 8days after the cessation of infusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704001"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Asahi Kasei Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asahi Kasei Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}